| Code | 3007F | ||||||||||
| MA number | 16/0098/26-S | ||||||||||
| Product Form: | cps dur 196(4x49)x2,5 mg/50 mg (blis.Al/OPA/Al/PVC-multibal.) | ||||||||||
| MA Status: | R - Valid Marketing Authorisation | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | Zentiva k.s., Czechia | ||||||||||
| Therapeutic Class: | 16 - ANTICOAGULANTIA (FIBRINOLYTICA, ANTIFIBRINOL.) | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 18 | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to medical prescription. |
| Legal basis: | Article 10b fixed combination application |
| MA issued: | 23.03.2026 |
| Validity: | 23.03.2031 |
| SPC: |
SPC_Xanirva DUO 2,5 mg_50 mg_03.2026.pdf
|
| PIL: |
PIL_Xanirva DUO 2,5 mg_50 mg_03.2026.pdf
|
| Safety feature | Yes |
| Data update: | 26.03.2026 |
